NZ593392A - Biomarker for detecting bladder cancer - Google Patents

Biomarker for detecting bladder cancer

Info

Publication number
NZ593392A
NZ593392A NZ593392A NZ59339209A NZ593392A NZ 593392 A NZ593392 A NZ 593392A NZ 593392 A NZ593392 A NZ 593392A NZ 59339209 A NZ59339209 A NZ 59339209A NZ 593392 A NZ593392 A NZ 593392A
Authority
NZ
New Zealand
Prior art keywords
bladder cancer
specific biomarker
patient
amount
cancer
Prior art date
Application number
NZ593392A
Other languages
English (en)
Inventor
Richard Morgan
Hardev S Pandha
Original Assignee
Univ Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Surrey filed Critical Univ Surrey
Publication of NZ593392A publication Critical patent/NZ593392A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NZ593392A 2008-12-23 2009-12-21 Biomarker for detecting bladder cancer NZ593392A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0823445.2A GB0823445D0 (en) 2008-12-23 2008-12-23 Biomarker
PCT/GB2009/002926 WO2010073001A1 (en) 2008-12-23 2009-12-21 Biomarker

Publications (1)

Publication Number Publication Date
NZ593392A true NZ593392A (en) 2013-05-31

Family

ID=40344114

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ593392A NZ593392A (en) 2008-12-23 2009-12-21 Biomarker for detecting bladder cancer

Country Status (15)

Country Link
US (1) US9624548B2 (enExample)
EP (1) EP2382327B1 (enExample)
JP (1) JP5947040B2 (enExample)
CN (1) CN102301006B (enExample)
AU (1) AU2009332712B2 (enExample)
BR (1) BRPI0923525A2 (enExample)
CA (1) CA2747760C (enExample)
ES (1) ES2725150T3 (enExample)
GB (1) GB0823445D0 (enExample)
IL (1) IL213510A (enExample)
MX (1) MX343251B (enExample)
NZ (1) NZ593392A (enExample)
RU (1) RU2573925C2 (enExample)
WO (1) WO2010073001A1 (enExample)
ZA (1) ZA201105184B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
JP5940093B2 (ja) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ 抗il−1rap抗体及びヒトを処置するためのそれらの使用
EP3479102A1 (en) * 2016-07-04 2019-05-08 CellTool GmbH Device and method for the determination of transfection
KR101777085B1 (ko) * 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
US20220389514A1 (en) 2019-10-02 2022-12-08 Kyushu University, National University Corporation Biomarker, method, kit and array for predicting therapeutic effects of bcg intravesical infusion therapy in treating bladder cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US7998695B2 (en) * 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
GB0625321D0 (en) * 2006-12-19 2007-01-24 Univ Surrey Cancer biomarker
PL2258871T3 (pl) * 2007-01-19 2014-10-31 Epigenomics Ag Sposoby i kwasy nukleinowe do analizy zaburzeń proliferacyjnych komórki
US20110003292A1 (en) 2007-12-11 2011-01-06 Dimo Dietrich Methods and nucleic acids for analyses of cell proliferative disorders

Also Published As

Publication number Publication date
WO2010073001A1 (en) 2010-07-01
GB0823445D0 (en) 2009-01-28
EP2382327A1 (en) 2011-11-02
CN102301006B (zh) 2015-07-15
MX343251B (es) 2016-10-31
IL213510A (en) 2016-04-21
RU2011130795A (ru) 2013-01-27
EP2382327B1 (en) 2019-02-13
RU2573925C2 (ru) 2016-01-27
JP2012513584A (ja) 2012-06-14
MX2011006773A (es) 2011-08-03
ZA201105184B (en) 2012-02-29
BRPI0923525A2 (pt) 2020-08-11
US20120020888A1 (en) 2012-01-26
IL213510A0 (en) 2011-07-31
CA2747760A1 (en) 2010-07-01
ES2725150T3 (es) 2019-09-19
CA2747760C (en) 2020-01-21
US9624548B2 (en) 2017-04-18
JP5947040B2 (ja) 2016-07-06
CN102301006A (zh) 2011-12-28
AU2009332712A1 (en) 2011-07-07
AU2009332712B2 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
BRPI0911925B8 (pt) Método para detectar um câncer
WO2008134526A3 (en) Glycoprotein profiling of bladder cancer
TWI317811B (enExample)
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
NZ603492A (en) Humanized anti-factor d antibodies and uses thereof
GB2467704A (en) Methods of monitoring conditions by sequence analysis
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2012075506A3 (en) Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
JP2008249727A5 (enExample)
CA2844033C (en) Method for detecting pancreatic cancer
JP2009504142A5 (enExample)
NZ586737A (en) Compositions and methods of detecting tiabs
WO2013093635A3 (en) Plasma micrornas for the detection of early colorectal cancer
MX345316B (es) Métodos y composiciones para diagnóstico y tratamiento del cáncer.
US10724097B2 (en) Methods and compositions for diagnosis and management of diabetes and metabolic syndrome
WO2008030186A8 (en) Diagnostic biomolecule(s)
WO2008012362A3 (en) New protein isoforms and uses thereof
PL2185937T3 (pl) Sposób wykrywania posocznicy u ludzi
EP2569635A4 (en) METHOD FOR DIAGNOSIS AND / OR TREATMENT OF ENZEPHALITIS OR EPILEPSY
BR112014020213A2 (pt) biomarcadores para o diagnóstico, o prognóstico, a avaliação e a estratificação de terapia de síncope
NZ598035A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2009141352A3 (en) Risk analysis in patients with and without metabolic syndrome
WO2010097553A3 (fr) Procédé de diagnostic d'une vascularite
WO2008116178A8 (en) Systems and methods for diagnosis and prognosis of colorectal cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 21 DEC 2016 BY LEA SKYLLERSTEDT

Effective date: 20131231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2017 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20161215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2018 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20171215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2019 BY DR. STEFFEN SCHWARZ IPRIS AG

Effective date: 20181213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 DEC 2020 BY DR. STEFFEN SCHWARZ

Effective date: 20191217

LAPS Patent lapsed